title: Total cumulative dose - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 413/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Total cumulative dose
  |
  |
  Route
  |
  IM
  |
  Preparation
  |
  Do not dilute or mix with any other medications
  Do not shake the vial
  |
  Administration
  |
  IM injection.
  Draw up required dose and administer into anterolateral thigh. Give injection volumes >1 mL as divided doses.
  |
  Monitoring
  |
  Hypersensitivity including anaphylaxis.
  |
  Contraindications
  |
  Palivizumab is contraindicated in patients with hypersensitivity to the active substance or other humanized monoclonal antibodies. [1]
  |
  Precautions
  |
  Keep all equipment needed for the treatment of severe hypersensitivity reactions ready before the administration of palivizumab.
  |
  Drug interactions
  |
  |
  Adverse reactions
  |
  These did not occur more commonly than in the placebo arm of a trial. [2].
  Common (>1%): fever, rash, rhinitis, wheeze, cough, diarrhoea, injection site reaction, cyanosis (in children with congenital heart disease); Infrequent (0.1–1%) anaemia, elevated liver enzymes;
  Rare (<0.1%) hypersensitivity (including anaphylaxis). [3]
  |
  Compatibility
  |
  Not applicable. Do not reconstitute palivizumab with any other diluents or medicinal components.
  |
  Incompatibility
  |
  Do not reconstitute palivizumab with any other diluents or medicinal components.
  |
  Stability
  |
  Administer immediately.
  |
  Storage
  |
  Refrigerate at 2O to 8 OC. Do not freeze. [1]
  |
  Excipients
  |
  Histidine and glycine and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL. [1]
  |
  |
  |
  | |